JOIN MAILING LIST

PRESENTATION

PIPELINE

INVESTORS

VIDEO

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Oramed’s ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study

November 29th, 2016|

Preparing to submit IND and commence U.S. FDA Phase IIb trial […]

Oramed Receives Additional $4 Million Milestone Payment From HTIT

October 6th, 2016|

Totaling $29.5 Million in payments from HTIT received to date

JERUSALEM, October […]